🇯🇵·6d agoIndustry
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
Publisher
S
Shionogi (IR News)
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on shionogi.com
Leave the platform to read the original full article on the publisher site.
Source: Shionogi (IR News)
Scope: Industry
Related coverage
More related coverage
Shionogi (IR News)·2d ago
Notice regarding the Bridge Loan Financing Related to Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
Shionogi (IR News)·2d ago
Shionogi Announces Approval in Japan of a Supplemental Indication for XOCOVA® (Ensitrelvir Fumaric Acid) for the Post-Exposure Prophylaxis of COVID-19.
GSK RSS·21h ago
Speeches and presentations
Sanofi News·1d ago
2026 03 24 06 00 00 3260948
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults wit...